Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India

Indian Journal of Medical Research

Volumn 120, Issue 3, 2004, Pages 166-172

  Thakur, C P ^a,c   Narayan, S ^b   Ranjan, A ^b  

^a Balaji Utthan Sansthan   (India)

^b Indira Gandhi Inst of Med Sciences   (India)

^c NONE   (India)

Author keywords

Antimony resistant; BALB c mice; In vitro; Visceral leishmaniasis (VL)

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B DEOXYCHOLATE; ANTIMONY GLUCONATE; CREATININE; HYDROCORTISONE; PARACETAMOL;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CARDIOTOXICITY; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG FATALITY; DRUG INFUSION; DRUG RESPONSE; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INDIA; LEISHMANIA DONOVANI; LIVER DISEASE; MACROPHAGE; MALE; MCNEMAR TEST; MOUSE; NONHUMAN; PARASITE CULTIVATION; PARASITE ISOLATION; PHLEBITIS; QT PROLONGATION; RIGOR; SHIVERING; STATISTICAL SIGNIFICANCE; TASTE DISORDER; VISCERAL LEISHMANIASIS;

ADULT; AMPHOTERICIN B; ANALYSIS OF VARIANCE; ANIMALS; ANTIMONY; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CHILD; DRUG RESISTANCE; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; MICE; MICE, INBRED BALB C; SPECTROPHOTOMETRY, ATOMIC;

EID: 6444223571     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Gupta PCS. Leishmaniasis. In: Banerjee JC, Bhattacharya BP, editors. A hand book of tropical diseases, 6th ed. Calcutta: Academic Publishers; 1960 p. 103-40.
2. Manson-Bahr PEC. Leishmaniasis. In: Wilcock C, Manson-Bahr PEC, editors. Manson's tropical diseases, 17th ed. London: English Book Society; 1972 p. 117-47.
3. Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 1984; 78: 391-8.
4. Peters W. The treatment of kala-azar-new approaches to an old problem. Indian J Med Res 1981; 73 (Suppl): 1-18.
5. Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 1984; 78 : 391-8.
6. Thakur CP, Kumar M, Singh SK, Sharma D, Prasad US, Singh RS, et al. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. BMJ 1984; 288 : 895-7.
7. Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalisation of regimen of treatment of kala-azar with sodium stibogluconate in India, a randomized study. BMJ 1988; 296 : 1557-61.
8. Thakur CP, Sinha GP, Sharma V, Pandey AK, Kumar M, Verma BB. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian J Med Res 1993; 97 : 170-5.
9. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31 : 1104-7.
10. Black CDV, Watson GJ. The use of pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans R Soc Trop Med Hyg 1977; 71: 550-2.
11. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95 : 668-72.
12. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999; 93 : 319-23.
13. Thakur CP. Correction of serum electrolyte imbalance prevents cardiac arrythmia during amphotericin B administration. Natl Med J India 1995; 8 : 13-4
14. Thakur CP. Sodium antimony gluconate, amphotericin and myocardial damage. Lancet 1998; 351 : 1928-9.
15. Berman JD, Chulay JD, Hendricks LD, Oster CN. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg 1982; 31 : 459-65.
16. Chang KP. Human cutaneous leishmania in mouse macrophases line. Propogation and isolation of intracellular parasites. Science 1980; 209 : 1240-2.
17. Bhatnagar S, Guru PY, Katiyar JC, Srivastava R, Mukherjee A, Akhtar MS, et al. Exploration of antileishmanial activity in heterocycles, results of their in vivo and in vitro bioevaluations. Indian J Med Res 1989; 89 : 439-44.
18. Chulay JD, Bryceson ADM. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32: 475-9.
19. Bradley DJ, Kirkley J. Regulation of Leishmania population within the host. I. The variable course of Leishmania donovani infection in mice. Clin Exp Immunol 1977; 30 : 119-29.
20. Trotter ER, Peters W, Robinson BL. The experimental chemotherapy of leishmaniasis. IV. The development of rodent model for visceral infection. Ann Trop Med Parasitol 1980; 74 : 127-38.
21. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, et al. Evidence that the high incidence of treatment failures in Indian Kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180 : 564-7.
22. Thakur CP, Dedet JP, Narain S, Pratlong F. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. Trans R Soc Trop Med Hyg 2001; 95 187-9.
23. Sacks DL, Kenney RT, Kreutzer RD, Jaffe CL, Gupta AK, Sharma MC, et al. Indian kala-azar caused by Leishmania tropica. Lancet 1995; 345: 959-61.
24. Handman E, Hocking RE, Mitchell GF, Spithill TW. Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol Biochem Parasitol 1983; 7: 111-26.
25. Grogl M, Oduola AM, Cordero LD, Kyle DE. Leishmania spp: development of pentostam-resistant clones in vitro by discontinous drug exposure. Exp Parasitol 1989; 69 : 78-90.
26. Pal S, Mandal A, Duttagupta S. Studies on stibanate resistant Leishmania donovani isolates of Indian origin. Indian J Exp Biol 2001; 39: 249-54.
27. Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob Agents Chemother 2003; 47 : 1529-35.
28. Thakur CP, Ahmed S. Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India. Indian J Med Res 2001; 113 : 14-8.
29. Datta G, Bera T. The effects of clofazimine, niclosamide & amphotericin B, on electron transport of Leishmania donovani promastigotes. Indian J Med Res 2000; 112 : 15-20.
30. Singh N, Singh RT, Sundar S. Identification of a gene linked to drug resistance in field isolates of Leishmania donovani. Ann Trop Med Parasitol 2002; 96 : 839-41.